Development of novel cell and gene therapies

新型细胞和基因疗法的开发

• 批准号: 8565300
• 负责人: David Stroncek
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8565300
• 关键词: Abnormal Cell; Acute Graft Versus Host Disease; Adjuvant; Allogenic; Antigen Receptors; Antigens; Autoimmune Diseases; Autologous; Bone Marrow; CD19 gene; Cancer Patient; Cancer Vaccines; Cell Therapy; Cell physiology; Cells; Childhood; Chronic Lymphocytic Leukemia; Clinical; Dendritic Cells; Development; ERBB2 gene; Enrollment; Failure; Growth Factor; Healed; Hematologic Neoplasms; Hematopoietic; Host Defense; Immune; Immune system; Laboratories; Laboratory Research; Legal patent; Malignant Neoplasms; Marrow; Medicine; Methods; Myocardial Ischemia; Natural Killer Cells; Operative Surgical Procedures; Patients; Peripheral Vascular Diseases; Play; Procedures; Process; Production; Protocols documentation; Reagent; Research Personnel; Stromal Cells; T cell therapy; T-Cell Receptor; Tissues; Transfusion; Transplant Recipients; Tumor-Infiltrating Lymphocytes; Work; base; cytokine; gene therapy; graft failure; healing; improved; instrument; melanoma; novel; patient oriented; scale up; stem; tissue regeneration; tumor

The cell processing laboratory is developing new natural killer (NK) cell, dendritic cell (DC), bone marrow stromal cell (BMSC) and chimeric antigen receptor (CAR) T cell therapies. NK cells are an important part of the innate immune system and they are thought play an important in host defense against foreign and abnormal cells including cancer and hematological malignancies. Preliminary work suggests that hematological malignancies can be treated by the administration of NK cells. The Cell Processing Laboratory has been expanding autologous and allogeneic NK cells to treat Clinical Center patients with cancer and hematological malignancies. Dendritic cells (DCs) are an important adjuvant for cancer vaccines. The Cell Processing Laboratory is currently providing DCs to Clinical Center patients enrolled in three different protocols. The laboratory is working on producing DCs expressing HER2/neu to treat cancer patients whose tumor express this antigen. Bone marrow stromal cells (BMSCs) can inhibit in function and support tissue regeneration Preliminary studies suggest that acute graft versus host disease and autoimmune diseases can be treated with BMSCs. In addition, BMSCs secrete cytokines and growth factor that improve the healing of damaged tissue and BMSCs have used to treat patients with ischemic heart disease and peripheral vascular disease. The Cell Processing Laboratory has developed a bank of BMSCs products collected from healthy subjects that is being used to treat hematopoietic stem transplant patients with acute graft versus host disease or graft failure. The lab has also developed a process to produce autologous BMSCs to treat patients with ischemic heart disease. Tumor infiltrating lymphocytes (TIL) are being used successfully by the Surgery Branch, NCI to treat patients with melanoma, but the production of these cells is difficult. The Cell Processing Laboratory worked with the Surgery Branch to develop new methods for TIL production. The cell processing laboratory has developed CAR T cells expressing anti-CD19. These cells are now being used to treat pediatric patents with B cell leukemias.

细胞处理实验室正在开发新的自然杀伤细胞（NK）、树突状细胞（DC）、骨髓基质细胞（BMSC）和嵌合抗原受体（CAR） T细胞疗法。